Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1785-1796

  Salphati, Laurent ^a   Pang, Jodie ^a   Plise, Emile G ^a   Lee, Leslie B ^a   Olivero, Alan G ^a   Prior, Wei Wei ^a   Sampath, Deepak ^a   Wong, Susan ^a   Zhang, Xiaolin ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [2 [2 AMINO PYRIMIDIN 5 YL] 7 METHYL 4 MORPHOLIN 4 YL THIENO[3,2 D]PYRIMIDIN 6 YLMETHYL] PIPERAZIN 1 YL] 2 HYDROXY PROPAN 1 ONE; BREAST CANCER RESISTANCE PROTEIN; CARBON 14; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GDC 0980; GLYCOPROTEIN P; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL STRAIN MCF 7; DOG; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GENETIC TRANSFECTION; HAPLORHINI; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; LIVER CLEARANCE; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BRAIN; BREAST NEOPLASMS; CELL MEMBRANE PERMEABILITY; DOGS; DRUG DOSAGE CALCULATIONS; FEMALE; HALF-LIFE; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; LIVER; MACACA FASCICULARIS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MCF-7 CELLS; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; P-GLYCOPROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TOR SERINE-THREONINE KINASES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865192520     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046052     Document Type: Article

References (33)

1. Bendell JC, Wagner AJ, Dolly S, Morgan JA, Papadatos-Pastos D, Ware JA, Mazina KE, Lauchle J, Burris H, and De Bono J (2010) A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). European Society for Medical Oncology (ESMO) Meeting; 2010 Oct 8-12, 2010; Milan, Italy. Abstract 4960. ESMO, Viganello-Lugano, Switzerland.
2. Benjamin D, Colombi M, Moroni C, and Hall MN (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10:868-880.
3. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227.
4. Castanedo G, Dotson J, Goldsmith R, Gunzner J, Heffron T, Mathieu S, Olivero A, Staben S, Sutherlin DP, Tsui V, et al. (2008) Phosphoinositide 3-kinase inhibitor compounds and methods of use. World patent WO/2008/073785. 2008 June 19.
5. Chalhoub N and Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127-150.
6. Ciraolo E, Morello F, and Hirsch E (2011) Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 18:2674-2685.
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
8. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562.
9. Engelman JA, Luo J, and Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619. (Pubitemid 44100518)
10. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51:5522-5532.
11. Gibaldi M and Perrier D (1982) Pharmacokinetics, Marcel Dekker, New York.
12. Gibbs JP (2010) Prediction of exposure-response relationships to support first-in-human study design. AAPS J 12:750-758.
13. Guertin DA and Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24.
14. Höland K, Salm F, and Arcaro A (2011) The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Curr Cancer Drug Targets 11:894-918.
15. Kalvass JC, Maurer TS, and Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666. (Pubitemid 46513270)
16. Liu P, Cheng H, Roberts TM, and Zhao JJ (2009a) Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Rev Drug Discov 8:627-644.
17. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, and Monshouwer M (2009b) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793.
18. Mahmood I and Balian JD (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
19. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508. (Pubitemid 43259931)
20. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
21. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, and Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] -amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
22. Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, et al. (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 100:4127-4157.
23. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100: 4090-4110.
24. Sabbah DA, Brattain MG, and Zhong H (2011) Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr Med Chem 18:5528-5544.
25. Salphati L, Lee LB, Pang J, Plise EG, and Zhang X (2010a) Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38:1422-1426.
26. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D, and Wallin JJ (2010b) Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38:1436-1442.
27. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, and Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101. (Pubitemid 38176915)
28. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J, et al. (2011) Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 54:7579-7587.
29. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, et al. (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602.
30. Wagner AJ, Burris HA, De Bono JS, Jayson GC, Bendell JC, Gomez-Roca C, Dolly S, Zee YK, Ware JA, Yan Y, et al. (2009) Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC-0980: Initial phase I evaluation. Mol Cancer Ther 8 (Suppl 1):B137.
31. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, et al. (2011) GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10:2426-2436.
32. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil F-P, Tibbitts J, Friedman LS, Hop CECA, et al. (2011) Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis. Mol Cancer Ther 10 (Suppl 1):A11.
33. Wong KK, Engelman JA, and Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:87-90.